OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC By Ogkologos - April 14, 2026 116 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 Getting Better Sleep When You Have Cancer-Related Insomnia: An Expert Q&A October 3, 2023 Qué debe saber sobre las pruebas de ADN en el hogar... February 8, 2023 Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of... March 26, 2026 Load more HOT NEWS Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ Can Eating Grilled or Charred Foods Cause Cancer? Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant...
